{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-093903","form_type":"8-K","ticker":null,"cik":"0001708331","company_name":"Virpax Pharmaceuticals, Inc.","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.127312+00:00","generated_at":"2026-06-07T16:16:35.977540+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Virpax appoints Gerald Bruce as CEO with $500K base salary and severance provisions","bullets":["Gerald Bruce appointed CEO of Virpax Pharmaceuticals, employment agreement dated December 6, 2023.","Annual base salary of $500,000; eligible for annual bonus up to 50% of base salary, based on Board-determined metrics.","Severance without cause or for good reason: 12 months base salary, medical premium reimbursement, and option vesting acceleration for 12 months.","Change in control severance: lump sum of 2x base salary plus 2x average bonus, with full equity acceleration."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-093903","json":"https://secwatch.observer/filing/0001213900-23-093903.json","markdown":"https://secwatch.observer/filing/0001213900-23-093903.md","text":"https://secwatch.observer/filing/0001213900-23-093903.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708331/000121390023093903/0001213900-23-093903-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708331/000121390023093903/ea189648-8k_virpaxpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:16:35.977540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a45f19b78e","claim":"Gerald Bruce was appointed as Chief Executive Officer at Virpax Pharmaceuticals, Inc..","evidence_excerpt":"On December 6, 2023, Virpax Pharmaceuticals, Inc. (the “Company”) entered into an employment agreement with Gerald Bruce (the “Bruce Employment Agreement”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000121390023093903/0001213900-23-093903-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}